Vapotherm Inc Closes $20 Million Series C Financing Round - Gilde Healthcare

Vapotherm Inc Closes $20 Million Series C Financing Round

13 March 2015

EXETER, NH – Vapotherm, Inc., a developer and manufacturer of advanced respiratory care technology, today announced the closing of a $20MM equity financing. 3×5 Specialty Opportunity Fund led the financing round, which also included current investors QuestMark Partners, Gilde Healthcare Partners, Morgenthaler Ventures, Kaiser Permanente, Adage Capital Management, Crestline Investors and Cross Creek Capital.

Tony Arnerich General Partner of 3×5 Special Opportunity Fund commented: “We are excited about Vapotherm’s unique High Flow Therapy solution which improves clinical outcomes for patients with chronic and acute breathing disorders.”

“This new capital will be used to continue to build out our direct sales organization in the U.S. and to develop our next generation solutions. We appreciate the continued support of our investors as we build a leading respiratory care company,” said Joe Army, President and CEO of Vapotherm.

Vapotherm, Inc. is a privately held developer and manufacturer of advanced respiratory care technology based in Exeter, New Hampshire. The company develops innovative, comfortable, noninvasive technologies for respiratory support of patients with chronic or acute breathing disorders. Over 700,000 patients have been treated with Vapotherm High Flow Therapy. For more information, visit www.vtherm.com.

Contact: John Landry, VP & CFO
T: (603) 658-0011

Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved...
5 October 2021

Gilde Healthcare portfolio company Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert...
4 October 2021

Gilde Healthcare company Acacia Pharma announces marketing authorization application for BARHEMSYS® in Europe

Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces...
29 September 2021